| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787866 | Journal of Thoracic Oncology | 2018 | 9 Pages |
Abstract
A baseline signature of a low ANC, high ALC, and high AEC was associated with a better outcome of nivolumab treatment, with the number of favorable factors identifying subgroups of patients differing in survival and response rate.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Junko MD, PhD, Koji MD, Hidetoshi MD, PhD, Yasutaka Chiba, Yasushi Nakamura, Kimio MD, PhD, Keita MD, PhD, Hiroyasu MD, PhD, Yoshikazu MD, PhD, Kaoru MD, PhD, Masayuki MD, PhD, Akihiko Ito, Kazuhiko MD, PhD,